Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
about
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisDefining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against AspergilluAspergillus infections in transplant recipients.Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.Epidemiology and treatment approaches in management of invasive fungal infectionsConcentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.Echinocandin antifungals: review and update.In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.The echinocandins.The use of caspofungin in HIV-infected individuals.Combination antifungal therapy: the new frontier.Combination antifungals: an update.Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistanceAmphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactionsEfficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.Echinocandin pharmacodynamics: review and clinical implications.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm.Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole.In vitro evaluation of antifungal drug combinations against Sarocladium (Acremonium) kiliense, an opportunistic emergent fungus resistant to antifungal therapies.Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.Comparison Between Etest and Broth Microdilution Methods for Testing Itraconazole-Resistant Aspergillus fumigatus Susceptibility to Antifungal Combinations.In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation.
P2860
Q28727508-66972EF3-0059-4B36-9ED9-D285E52F1F65Q33517581-25B4882C-3192-427B-A56A-D45EB92E60FFQ33719294-B29B6F76-7E8A-4136-B8E6-0971AB0BB55EQ34228354-AF0D8AD3-BE50-4EF9-9864-03201FB522EEQ35089772-D794320E-EB64-43B1-8205-AE33957C6D04Q35840760-C062D3CD-E829-4F37-9F13-03A8E5AAE4B0Q36441524-70B2C85A-6618-481E-AA33-EA0E3E9A8552Q36558484-E61138C2-95E4-475D-873F-46104BE8FDB8Q36742397-F23A2EB2-8E7F-4E7A-B40D-BA6147130C37Q36821383-AA4F9EEA-73DA-4C55-A1B2-AB65670A64BFQ36895652-1F5C8F6C-1C34-4490-A41B-10712ADF20D5Q36960092-6138CB90-0151-49E0-92C7-B37562DDFF7EQ37122826-D2FE90F9-1473-4F8F-8749-7FB0DA3ECB05Q37263780-8B3960D2-D772-4397-8124-B534C6440D43Q37558822-00BAACBA-C610-4E85-A961-50C922A7D215Q37718385-6809B8BD-A7FC-4F2E-B8AB-9E3807D257DAQ38586680-E6AF0DD9-FDA1-481D-8A91-980CA6ED094FQ40337564-83546D83-C1F3-408C-86CB-54C4E0DB39DCQ41835779-9709C557-0544-4E37-87F4-A099292E4B21Q41973262-7862C3BE-9C65-401D-9474-F116CD4D041DQ42032764-B9711B74-40EE-4EDA-8976-D79C2DC6334DQ42146568-D261F448-E41E-477B-9122-2467F26B21C5Q42573050-79A5A4AA-C122-444D-8AF6-D39175B14520Q42689671-DEAC0450-F293-4DDB-B3D4-EEFF55631474Q42956812-8E5F0605-E35C-4183-A4F6-45C5E9C94986Q43183398-EAB5489B-5774-4EEE-8165-3DA797082C0AQ44619968-F2EF1EDD-800D-447B-8213-4731DF2DB371Q46290055-80F991EE-16A6-40D3-9A9F-321957830099Q48179374-C2606475-F971-466B-A6AE-EB5AED650BDAQ51186226-FCF92D77-D3A0-4DA0-916B-6F4BFA75D968
P2860
Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Combined activity in vitro of ...... ates of Aspergillus fumigatus.
@ast
Combined activity in vitro of ...... ates of Aspergillus fumigatus.
@en
type
label
Combined activity in vitro of ...... ates of Aspergillus fumigatus.
@ast
Combined activity in vitro of ...... ates of Aspergillus fumigatus.
@en
prefLabel
Combined activity in vitro of ...... ates of Aspergillus fumigatus.
@ast
Combined activity in vitro of ...... ates of Aspergillus fumigatus.
@en
P2093
P2860
P1476
Combined activity in vitro of ...... ates of Aspergillus fumigatus.
@en
P2093
Alicia Gomez-Lopez
Emilia Mellado
Guillermo Garcia-Effron
Juan L Rodriguez-Tudela
Laura Alcazar-Fuoli
Manuel Cuenca-Estrella
Maria J Buitrago
P2860
P304
P356
10.1128/AAC.49.3.1232-1235.2005
P407
P577
2005-03-01T00:00:00Z